Korro Bio Announces Major Restructuring and Program Shifts
Korro Bio is focusing on new genetic medicines (GalNAc programs) after poor trial results for KRRO-110, pausing its Novo Nordisk partnership, and reducing its staff by 34%.
Korro Bio is focusing on new genetic medicines (GalNAc programs) after poor trial results for KRRO-110, pausing its Novo Nordisk partnership, and reducing its staff by 34%.
Flutter Entertainment cuts 2025 profit outlook to $2.9B as gamblers' winning streaks hit payouts. Company launches FanDuel Predicts app to tap prediction markets opportunity.
JD.com's (JD) Q3 revenue surged 15% to $42B, surpassing estimates with Singles Day success and 700M active users, though net income dropped 55% amid aggressive expansion into food delivery.
Serve Robotics CEO Ali Kashani believes ads on its autonomous delivery robots could one day cover full operational costs, even as Q3 results miss.
Cisco Systems reported strong quarterly results and raised its sales outlook, driven by booming AI infrastructure demand and campus network upgrades.
LivaNova outlines a strong 2030 roadmap with targets for high revenue growth, expanded margins, and new innovations in Epilepsy, Cardiopulmonary, and Sleep Apnea treatments.